Webinar: Medical Devices

Medical Device Reforms

Australia's medical device sector is undergoing a major regulatory shake-up in 2026, driven by the Therapeutic Goods Administration's push for greater safety and accountability. Key changes include the introduction of mandatory adverse event reporting for all hospitals, set to begin on March 21. This requires public, private, and day facilities to notify the TGA of any device-related injuries or near-misses, starting with high-risk items and expanding over four years. The move aims to catch safety issues earlier, following international trends where under-reporting has led to scandals like faulty implants affecting thousands.

Parallel reforms target software and AI-based devices, with new guidance clarifying when algorithms qualify as medical devices. Released in February 2026, these rules emphasize risk management and cybersecurity, prioritizing compliance in areas like diagnostic AI tools. Manufacturers must align with standards by mid-year, or face exclusion from the Australian Register of Therapeutic Goods. This reflects a broader response to a 2025 review highlighting AI's potential risks in healthcare, where biased algorithms could exacerbate inequalities.

Another critical update is the Unique Device Identification system, becoming mandatory for implantable devices from July 2026. Sponsors must barcode products and upload data to the AusUDID database, enabling precise tracking in patient records. While this promises to reduce errors—such as those in recalls costing millions—it imposes upfront costs estimated at AUD 50,000-200,000 per firm for system integration. Boundary amendments from January 1 reclassify items like faecal management systems as devices, with a five-year transition ending in 2031, during which non-compliant products could be pulled.

Stakes are high: reclassification applications are due by July 1, 2026, for certain entries, with extensions only for compelling reasons. Non-compliance risks fines up to AUD 1.1 million per offence, plus reputational damage. For hospitals, inaction could mean legal liabilities if unreported incidents lead to lawsuits, as seen in past cases involving hip replacements. Patients stand to benefit from faster recalls, potentially averting harms like the 2024 ventilator failures that injured 150 Australians.

Less obvious tensions arise between innovation and oversight. AI developers argue strict rules stifle startups, with compliance burdens favoring big players like those in the US or EU. Yet, the TGA's proactive enforcement—outlined in its 2026-2027 principles—targets high-risk areas, balancing this by accepting FDA approvals for some devices since October 2024. Trade-offs include potential over-reporting overwhelming the TGA, or data privacy concerns in UDI integration with My Health Record. Surprisingly, these changes could lower long-term costs by AUD 10 million annually through streamlined audits, but initial hurdles may delay market entry for cutting-edge tech.